GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sotac Pharmaceuticals Ltd (NSE:SOTAC) » Definitions » Return-on-Tangible-Asset

Sotac Pharmaceuticals (NSE:SOTAC) Return-on-Tangible-Asset : 1.62% (As of Sep. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Sotac Pharmaceuticals Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Sotac Pharmaceuticals's annualized Net Income for the quarter that ended in Sep. 2024 was ₹18 Mil. Sotac Pharmaceuticals's average total tangible assets for the quarter that ended in Sep. 2024 was ₹1,136 Mil. Therefore, Sotac Pharmaceuticals's annualized Return-on-Tangible-Asset for the quarter that ended in Sep. 2024 was 1.62%.

The historical rank and industry rank for Sotac Pharmaceuticals's Return-on-Tangible-Asset or its related term are showing as below:

NSE:SOTAC' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -7.27   Med: 2.59   Max: 5.38
Current: 4.26

During the past 5 years, Sotac Pharmaceuticals's highest Return-on-Tangible-Asset was 5.38%. The lowest was -7.27%. And the median was 2.59%.

NSE:SOTAC's Return-on-Tangible-Asset is ranked better than
58.08% of 1021 companies
in the Drug Manufacturers industry
Industry Median: 2.68 vs NSE:SOTAC: 4.26

Sotac Pharmaceuticals Return-on-Tangible-Asset Historical Data

The historical data trend for Sotac Pharmaceuticals's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sotac Pharmaceuticals Return-on-Tangible-Asset Chart

Sotac Pharmaceuticals Annual Data
Trend Mar20 Mar21 Mar22 Mar23 Mar24
Return-on-Tangible-Asset
0.29 -7.27 - 5.38 4.89

Sotac Pharmaceuticals Quarterly Data
Mar20 Mar21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.68 3.72 6.36 5.62 1.62

Competitive Comparison of Sotac Pharmaceuticals's Return-on-Tangible-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Sotac Pharmaceuticals's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sotac Pharmaceuticals's Return-on-Tangible-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sotac Pharmaceuticals's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Sotac Pharmaceuticals's Return-on-Tangible-Asset falls into.


;
;

Sotac Pharmaceuticals Return-on-Tangible-Asset Calculation

Sotac Pharmaceuticals's annualized Return-on-Tangible-Asset for the fiscal year that ended in Mar. 2024 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Mar. 2024 )  (A: Mar. 2023 )(A: Mar. 2024 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Mar. 2024 )  (A: Mar. 2023 )(A: Mar. 2024 )
=42.813/( (717.298+1034.127)/ 2 )
=42.813/875.7125
=4.89 %

Sotac Pharmaceuticals's annualized Return-on-Tangible-Asset for the quarter that ended in Sep. 2024 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Sep. 2024 )  (Q: Jun. 2024 )(Q: Sep. 2024 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Sep. 2024 )  (Q: Jun. 2024 )(Q: Sep. 2024 )
=18.368/( (0+1135.81)/ 1 )
=18.368/1135.81
=1.62 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Sep. 2024) net income data.


Sotac Pharmaceuticals  (NSE:SOTAC) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Sotac Pharmaceuticals Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Sotac Pharmaceuticals's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Sotac Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
Plot No. PF-21, Near ACME Pharma, Opposite Teva Pharma Sanand GIDC-II, Sanand, Ahmedabad, GJ, IND, 382110
Sotac Pharmaceuticals Ltd is a pharma manufacturer, specializing in the manufacturing of a wide range of pharmaceutical products such as Non-Beta-Lactam (general) tablets, beta-lactam coated tablets, beta-lactam uncoated tablets, Non-Beta-Lactam (general) capsules, beta-lactam capsules, oral liquid, dry syrup and external preparations such as nasal spray, relief spray, and cream.

Sotac Pharmaceuticals Headlines

No Headlines